IntraBio

IntraBio is a late-stage biopharmaceutical company developing novel therapies for rare (“orphan”) and common neurodegenerative diseases

[IntraBio @IntraBio]

IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort https://t.co/xWLKJRGPS2

[IntraBio @IntraBio]

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)

https://t.co/I42rifjHeW

[IntraBio @IntraBio]

IntraBio Appoints Jim Meyers as President and CEO
https://t.co/YxLONDEGJV

[IntraBio @IntraBio]

Professor Michael Strupp Receives the 2020 Galenus-von-Pergamon Award

https://t.co/6Kzz0fOeQj

[IntraBio @IntraBio]

IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C https://t.co/xyunE4eO6H

[IntraBio @IntraBio]

New hope for Treatment Against Niemann-Pick disease Type C https://t.co/oBT7C0RbL9 via @Business News Tribune

[IntraBio @IntraBio]

"IntraBio Reports Positive Data from NPC Study" - @GlobalGenes

https://t.co/qkaH1URGNq

[IntraBio @IntraBio]

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C https://t.co/FwSlfep88e

[NNPDF @nnpdf]

JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: https://t.co/DEbdE5Ybh6

#NPC #niemannpick #nnpdf

[IntraBio @IntraBio]

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease #IntraBio #Ataxia #FDA #Biotech

https://t.co/0J6RS9SnQT

[IntraBio @IntraBio]

IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease #IntraBio #MHRA #NPC

https://t.co/pR2UpHyTL6

[IntraBio @IntraBio]

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease #Biotech #FDA #IntraBio #IND

https://t.co/WlPfRS0Js5

[IntraBio @IntraBio]

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease #Biotech #FDA #IntraBio

https://t.co/LxqIFfsUxr

[IntraBio @IntraBio]

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 #RareDisease #Biotech #IntraBio

https://t.co/I53AEfYQ0C

[IntraBio @IntraBio]

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 #RareDisease #FDA #Biotech #IntraBio
https://t.co/9HwsbVcfMN

[IntraBio @IntraBio]

IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA #RareDisease #Biotech #IntraBio

https://t.co/49Tu1AAX4Q

[IntraBio @IntraBio]

RareDaily reports on our recent Rare Pediatric Disease Designation for Niemann-Pick disease Type C for our lead compound series
https://t.co/X7paklrYQ6 via @GlobalGenes

[IntraBio @IntraBio]

IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA #IntraBio #Ataxia #RareDisease #Biotech

https://t.co/pb34JH6nbi

[IntraBio @IntraBio]

IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of Spinocerebellar Ataxia #RareDisease #Ataxia #IntraBio

https://t.co/LQhKlmqhuZ

[IntraBio @IntraBio]

IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series #RareDisease #OrphanDisease #Biotech #NiemannPick #FDA #IntraBio

https://t.co/J8PytqPU2i